drugset / Trial / NCT03238703
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.
Timeline
- Start
- 2018-09-01
- Primary completion
- 2023-03-14
- Completion
- 2025-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | Oral |
| Subject | Exemestane | Small molecule | — | Oral |
| Subject | Letrozole | Other / unclassified | — | Oral |
| Subject | Tamoxifen | Small molecule | — | Oral |
| Subject | Toremifene | Small molecule | — | Oral |